These CAR-T cells demonstrated superior tumor suppression in T-cell lymphoma compared to NbCD30-CAR-T cells, NbCD5-CAR-T cells, and scFv-based bispecific CD30-CD5-CAR-T cells [110]. In another study, anti-CD19 and CD20 nanobodies with high specificity and affinity were selected from a naïve phage Nb display library to generate bispecific CAR-T cells. The CD19/CD20 bispecific CAR-T cells showed robust cytotoxic activity against Raji and Daudi cells, which endogenously express both CD19 and CD20. This evidence concerns the gene CD19 and T-cell non-Hodgkin lymphoma.